GSK/XenoPort Prep RLS Candidate For Phase III In Neuropathic Pain
This article was originally published in The Pink Sheet Daily
Firms plan to initiate pivotal trials of XP13512 in neuropathic pain this year after releasing positive Phase III data for restless legs syndrome.
You may also be interested in...
Extended-release ropinirole uses Skye’s proprietary GeoMatrix technology to provide steady levels over 24 hours.
XP13512 is in Phase III development for restless legs syndrome and Phase II for neuropathic pain.
Sanofi will fill and package 100 million doses of a rival vaccine for the European market in 2021 in a sign of how the industry is working to meet an unprecedented demand for COVID-19 vaccines.